drugset / Trial / NCT01596140
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied. Vemurafenib is designed to block BRAF inside the cancer cells, which is a mutation that is involved in cancer cell growth. Temsirolimus and everolimus are designed to block the growth of cancer cells, which may cause cancer cells to die.
Timeline
- Start
- 2012-12-18
- Primary completion
- 2020-06-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Temsirolimus | Small molecule | 15 mg | Intravenous |
| Subject | Vemurafenib | Small molecule | 720 mg | Oral |